Earth Science Tech Inc. (ETST)

[Bigjohn6500]

Earth Science Tech, Inc. Shares Progress on its Cannabis (CBD) Patent FormulasPress Release | 07/10/2018
DORAL, Florida, July 10, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (ETST" or the Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, as well as research and development, is pleased to share progress on the companys CBD IP patent formula development program.

Mentioned in June, the Company currently developing three new CBD formulas and already under the provisory patent.

Two of them are very unique CBD formula products a neuron protector and a breast protector. The company is very bullish on these CBD formulas as the R&D done by the Centre de dveloppement bioalimentaire du Qubec (CDBQ) or Quebec Agrifood Innovation Center (QAIC) has been very promising. The team at CDBQ is highly experienced and able to employ the most effective and economical solutions to develop products with the best price-quality ratio on the market. CDBQ is now working on the final formulation that will include an as-yet undetermined natural protective agent to assure the longest possible shelf life of the CBD formula. Several alternatives are now being meticulously tested.

The third CBD formula is a new type of superfood with unique organoleptic properties never seen on the market. Formulated from a mix of hemp oil and other vegetal oil(s), and enriched with a highly potent antioxidant, this product is designed to improve the individuals antioxidant ingestion. The Company has developed this CBD formula with experts that have successfully developed products for some of the largest players in the food industry.

The Company also has two products in development as part of a Joint Venture with Bionatus Laboratrio Botnico of Brazil and its Canadian division Bionatus Botanical Laboratories, Inc.

We are already at work with Bionatus in Brazil and in Canada on the manufacture of the first product, Propovit enriched with ETST hemp oil. We are also working on a reformulation of Bionatus product, stated ETST CEO and Chief Science Officer, Dr. Michel Aube. The new formulation will see the product enriched with CBD to boost the suspected anti-inflammatory and bronchial-dilatation properties of the main natural ingredient - Guaco (Mikania glomerata) extract (http://www.bionatus.ca/index.php/en-ca/blog).

Guaco is a Brazilian plant widely used to help treat respiratory conditions. The Brazilian Health Regulatory Agency (ANVISA) has encouraged the use of Guaco, as its effectiveness has been proven by traditional use and the product is widely available OTC in Brazil. Guacos actions as an anti-inflammatory, an anti-edema agent, and a bronchodilator have been proven through in-vivo studies using extracts of Mikania glomerata.

ETST and Bionatus have planned a new product that will combine the effects of Mikania glomerata and Cannabis sativa oil for specific patients. Details will be forthcoming shortly.

Andr Konan PhD , Director of the Laboratory Bionatus Pharmacognosique Inc. states: As we move forward in this project, research results on CBD as well as clinical trials on Guaco and Brazilian honey used in Propovit are increasingly being published. This allows us to better focus our research to bring more innovative products to the market.

The Company plans to share further updates on its CBD IP patent formula, research and development, Form 10 approval, and medical device updates as each progresses.